Health In Tech earnings release, August 13, 2026
Health
In Tech Reports Second Quarter 2026 Financial Results
Contracted
Revenue of $32.3 Million as of June 30, 2026
Pipeline
Revenue of $66.3 Million as of July 31, 2026
Distribution
Partners Grew 19.9% Year Over Year
Stuart,
FL., August 13, 2026 /PRNewswire/ — Health In Tech, Inc. (Nasdaq: HIT) (“Health In Tech” or the “Company”), an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three and six months ended June 30,
2026.
Second
Quarter and First-Half 2026 Highlights
2026
Outlook and Beyond
As of July 31, 2026, the Company had approximately $66.3 million in Pipeline Revenue, of which $1.9 million was contracted, while the remaining
$64.4 million is in the quoting or binding stage. Based on the Company’s estimated conversion rate of 15% to 40%, the Pipeline
Revenue in the quoting or binding stage is expected to generate approximately $9.7 million to $25.8 million of additional Contracted
Revenue. Under U.S. GAAP revenue recognition, this is expected to result in approximately $3.1 million to $8.3 million of GAAP revenue recognized in 2026, with an additional $6.6 million to $17.5 million of GAAP revenue expected to be recognized in 2027.
With five more months remaining in 2026, the Company expects to continue expanding its Pipeline Revenue through new product launches and new system enhancement. Supported by its growing base of Contracted Revenue, increasing forward revenue visibility, and continued pipeline development, the Company is reaffirming its full-year 2026 revenue guidance of $45 million to $50 million.
CEO
Commentary
Tim
Johnson, Chief Executive Officer of Health In Tech, commented, “We continued to execute against our long-term growth strategy during the quarter by investing in sales, marketing, and key talent, supported in part by the capital raised through our recent PIPE financing.
These investments are designed to expand our distribution network, accelerate product innovation, and strengthen our execution capabilities.
Our contracted book of business continued to grow, providing greater visibility into future revenue. We believe Contracted Revenue and
Pipeline Revenue are meaningful operating metrics that complement our GAAP financial results by illustrating the strength of our sales pipeline, the pace of customer conversion, and our expected revenue trajectory.”
Mr.
Johnson continued, “We also made meaningful progress on several strategic initiatives that we believe position the Company for its next phase of growth. During the quarter, we contractually secured our first employer group for the Three-Year Rate Stabilization
Program, a differentiated solution designed to provide employers with greater predictability in stop-loss pricing over a multi-year period.
This represents an important milestone as we advance toward the program’s anticipated launch in the capital markets. In parallel, we are engaged with several high-profile governmental organizations that are evaluating participation in the program, and we expect to provide additional updates in the coming months.
As we execute on our strategic roadmap, we remain on track to launch
HitRix, our next-generation marketplace platform, in the second half of 2026. While our current eDIYBS platform has transformed AI-enabled underwriting through bindable stop-loss quoting and customized plan design, HitRix expands the application of AI across the entire self-funded stop-loss insurance ecosystem. The platform leverages advanced AI-powered document intelligence to automate data extraction across multiple document types, enable intelligent plan comparisons, and facilitate an integrated competitive bidding process within a unified digital marketplace. By connecting a broad network of brokers, carriers, TPAs, and employer groups, HitRix is designed to increase market transparency, expand access to competitive stop-loss solutions, streamline the placement process, and deliver better outcomes for all participants across the self-funded insurance value chain.”
End
Notes²
Conference
Call Details
Health
In Tech will host a conference call to discuss its financial results for the second quarter of 2026 on August 13, 2026, at 5:00 p.m.
(ET). To participate in our live conference call and webcast, please dial 1-888-346-8982 or 1-412-902-4272 (for international participants).
A live audio webcast will be available via the Investor Relations page of Health In Tech’s website at https://healthintech.com/.
A replay of the webcast will be available for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.
Non-GAAP
Financial Information
This release presents Adjusted EBITDA, a non-GAAP financial metric, which is provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Management uses Adjusted EBITDA to provide investors with additional insight into operational performance and to facilitate comparison with other companies in the industry.
Adjusted EBITDA should not be considered an alternative to net income, operating income, or other GAAP measures. A reconciliation of historical non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release.³
Financial statements
Income Statement
Three Months Ended June 30, — (Unaudited)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Revenues | Revenues from underwriting modeling (ICE) | 1,272,647 | 2,090,576 | 2,741,461 | 4,442,560 |
| Revenues | Revenues from fees (SMR) | 6,783,973 | 7,223,273 | 14,086,805 | 12,886,273 |
| Revenues | Total revenues | 8,056,620 | 9,313,849 | 16,828,266 | 17,328,833 |
| Revenues | Cost of revenues | 4,134,127 | 3,003,979 | 8,396,374 | 5,663,564 |
| Revenues | Gross profit | 3,922,493 | 6,309,870 | 8,431,892 | 11,665,269 |
| Operating expenses | Sales and marketing expenses | 2,215,889 | 1,226,738 | 4,507,490 | 2,316,993 |
| Operating expenses | General and administrative expenses | 4,269,094 | 3,775,453 | 7,724,652 | 7,022,218 |
| Operating expenses | Research and development expenses | 875,811 | 582,609 | 1,796,206 | 1,120,330 |
| Operating expenses | Total operating expenses | 7,360,794 | 5,584,800 | 14,028,348 | 10,459,541 |
| Other income (expense): | Interest income | 69,568 | 108,198 | 137,039 | 193,564 |
| Other income (expense): | Other income | 100,000 | 122,334 | 118,399 | |
| Other income (expense): | Other expense | -52,341 | -52,341 | ||
| Other income (expense): | Total other income, net | 117,227 | 108,198 | 207,032 | 311,963 |
| Other income (expense): | (Loss) income before income tax expense | -3,321,074 | 833,268 | -5,389,424 | 1,517,691 |
| Other income (expense): | Income tax benefit (expense) | 809,888 | -202,637 | 1,289,957 | -388,468 |
| Other income (expense): | Net (loss) income | -2,511,186 | 630,631 | -4,099,467 | 1,129,223 |
| Other income (expense): | Net loss attributable to noncontrolling interests | -162 | -162 | ||
| Other income (expense): | Net (loss) income attributable to common stockholders | -2,511,024 | 630,631 | -4,099,305 | 1,129,223 |
| Net (loss) income per share | Basic | -0.04 | 0.01 | -0.07 | 0.02 |
| Net (loss) income per share | Diluted | -0.04 | 0.01 | -0.07 | 0.02 |
| Weighted average common shares outstanding: | Basic | 62,829,725 | 55,382,395 | 60,106,502 | 55,003,233 |
| Weighted average common shares outstanding: | Diluted | 62,829,725 | 55,632,357 | 60,106,502 | 57,004,070 |
Balance Sheet
December 31, — (Unaudited)
| June 30, – 2026 | December 31, – 2025 | ||
|---|---|---|---|
| Current assets | Cash and cash equivalents | 6,514,813 | 7,669,754 |
| Current assets | Accounts receivable, net | 8,546,307 | 756,288 |
| Current assets | Loans receivable, net | 847,993 | 815,995 |
| Current assets | Other receivables, net | 3,392,082 | 3,467,814 |
| Current assets | Deferred offering costs | 102,586 | 170,977 |
| Current assets | Prepaid expenses and other current assets | 2,380,284 | 3,280,148 |
| Current assets | Total current assets | 21,784,065 | 16,160,976 |
| Non-current assets | Software | 7,197,718 | 6,530,894 |
| Non-current assets | Operating lease - right-of-use assets | 104,277 | 139,940 |
| Non-current assets | Long-term prepaid expenses | 8,184 | 258,151 |
| Non-current assets | Deferred tax assets, net | 540,436 | |
| Non-current assets | Total non-current assets | 7,850,615 | 6,928,985 |
| Non-current assets | Total assets | 29,634,680 | 23,089,961 |
| Current liabilities | Accounts payable and accrued expenses | 9,907,370 | 4,188,811 |
| Current liabilities | Operating lease liabilities - current | 81,225 | 76,195 |
| Current liabilities | Other current liabilities | 891,598 | |
| Current liabilities | Total current liabilities | 9,988,595 | 5,156,604 |
| Non-current liabilities | Deferred tax liabilities | 757,675 | |
| Non-current liabilities | Operating lease liabilities - non-current | 21,713 | 63,617 |
| Non-current liabilities | Total non-current liabilities | 21,713 | 821,292 |
| Non-current liabilities | Total liabilities | 10,010,308 | 5,977,896 |
| Stockholders’ equity | Common stock, $0.001 par value; Class A Common stock 150,000,000 shares authorized 53,858,083 and 46,006,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 53,858 | 46,006 |
| Stockholders’ equity | Common stock, $0.001 par value; Class B Common stock 50,000,000 shares authorized, 11,700,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 11,700 | 11,700 |
| Stockholders’ equity | Additional paid-in capital | 18,365,473 | 11,834,121 |
| Stockholders’ equity | Retained earnings | 1,120,933 | 5,220,238 |
| Stockholders’ equity | Noncontrolling interests | 72,408 | |
| Stockholders’ equity | Total stockholders’ equity | 19,624,372 | 17,112,065 |
| Stockholders’ equity | Total liabilities and stockholders’ equity | 29,634,680 | 23,089,961 |
Cash Flow
Three Months Ended June 30, — (Unaudited)
| Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 | Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | ||
|---|---|---|---|---|---|
| Cash flows (used in) provided by operating activities: | Net (loss) income | -2,511,186 | 630,631 | -4,099,467 | 1,129,223 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | Bad debt (recovery) expense | -2,954 | 5,990 | -2,954 | 5,990 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | Amortization expense | 320,320 | 135,983 | 723,787 | 271,966 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | Provision for refund liability | 175,698 | 108,402 | 955,743 | |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | Provision for credit losses on other receivables | 739,773 | 739,773 | ||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | Deferred tax benefit | -813,639 | -32,074 | -1,298,111 | -66,547 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | Interest income | -15,999 | -15,999 | -31,998 | -31,998 |
Full release
Use of Forward-Looking Statements
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about Health In Tech’s possible... (truncated)sition, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,”
“will,” “should,” “design,” “target,” “aim,” “hope,” “expect,”
“could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,”
“continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to Health In Tech’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause Health In Tech’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond Health In Tech’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects
Health In Tech’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to Health In Tech’s operations, results of operations, growth strategy and liquidity.
About
Health In Tech
Health
In Tech, Inc. (Nasdaq: HIT) is an AI-enabled InsurTech platform company, which offers a marketplace that improves processes in the health insurance industry through vertical integration, process simplification, and automation. By removing friction and complexities, we streamline the underwriting, sales and service process for insurance companies, licensed brokers, Managing General Underwriter (“MGUs”) and third-party administrators (“TPAs”). Health In Tech’s platform serves as a marketplace for brokers, TPAs, MGUs and carriers to access self-funded health insurance for employers, providing functions including customized self-funded health plans, bindable stop-loss quotes, AI-enabled underwriting, claims administration and reporting integration.⁴
Health
In Tech, Inc.
Consolidated
Statements of Operations
(Unaudited)⁵
Reconciliation of Net (Loss) Income Attributable to Common Stockholders to Adjusted EBITDA
(Unaudited)⁶
Consolidated
Balance Sheets
(Unaudited)⁷
Consolidated
Statements of Cash Flows
(Unaudited)
Investor
Contact:
Health
In Tech Investor Relations ir@healthintech.com⁸